← Leaderboards
Katy Rezvani
University Of Tx Md Anderson Can Ctr
$10,195,970
Attributed
$14,678,016
Total exposure
11
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,678,016 · 11
By mechanism
R01$7,551,451 · 5
P50$2,738,956 · 3
P01$2,480,049 · 1
T32$1,517,702 · 1
R21$389,858 · 1
Top collaborators
- Rafet Basar6 shared
- Elizabeth J Shpall5 shared
- May Daher4 shared
- Michael Davies3 shared
- Hind Rafei2 shared
- Richard J Simpson2 shared
- Juan Fueyo1 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Rafet Basar$1,227,277
- Anil K Sood$29,572,737
- May Daher$980,227
- Sattva S Neelapu$3,334,171
- Hind Rafei$247,050
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsUmbilical Cord BloodToxic EffectSignal TransductionDoseCell TherapyNatural Killer CellsCytokineProtocols DocumentationInterleukin-15SafetyAllogenicT-LymphocyteSpecificityImproved OutcomeGenerationsCasp9 GeneClinical ResearchCellular TransductionMediatingNovel StrategiesRetroviral VectorChimeric Antigen ReceptorAdoptive Transfer
Grant awards (37)
Advancing next-generation CAR-NK therapies targeting CD5 positive T cell malignancies to the clinic$1,847,485
R01 · FY2025 · CA · contact PI
TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer$370,575
R01 · FY2025 · CA
Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure.$370,575
R01 · FY2025 · CA
Next-Generation Engineered NK Cell Immunotherapy for Ovarian Cancer$273,109
P50 · FY2025 · CA · contact PI
TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer$370,575
R01 · FY2024 · CA
Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure.$352,047
R01 · FY2024 · CA
Next-Generation Engineered NK Cell Immunotherapy for Ovarian Cancer$319,497
P50 · FY2024 · CA · contact PI
Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure.$370,575
R01 · FY2023 · CA
Next-Generation Engineered NK Cell Immunotherapy for Ovarian Cancer$306,595
P50 · FY2023 · CA · contact PI
Project 4: Off-the-shelf engineered cord blood-derived natural killer cells for the treatment acute lymphoblastic leukemia$293,401
P50 · FY2023 · CA · contact PI
Research Training in Academic Medical Oncology$591,629
T32 · FY2022 · CA
Off-the-Shelf Engineered Cord Blood NK Cells for the Treatment of Hematologic Malignancies.$493,218
P01 · FY2022 · CA · contact PI
Project 4: Off-the-shelf engineered cord blood-derived natural killer cells for the treatment acute lymphoblastic leukemia$272,372
P50 · FY2022 · CA · contact PI
Research Training in Academic Medical Oncology$563,952
T32 · FY2021 · CA
Off-the-Shelf Engineered Cord Blood NK Cells for the Treatment of Hematologic Malignancies.$493,690
P01 · FY2021 · CA · contact PI
Off-the-shelf engineered NK cells for the treatment of AML$366,000
R01 · FY2021 · CA · contact PI
Project 4: Off-the-shelf engineered cord blood-derived natural killer cells for the treatment acute lymphoblastic leukemia$272,372
P50 · FY2021 · CA · contact PI
Off-the-shelf Genetically Engineered Natural Killer Therapy for Glioblastoma$258,822
P50 · FY2021 · CA · contact PI
Off-the-Shelf Engineered Cord Blood NK Cells for the Treatment of Hematologic Malignancies.$494,368
P01 · FY2020 · CA · contact PI
Hematopoietic Progenitor Cells- Cord Blood$380,000
R01 · FY2020 · CA
Off-the-shelf engineered NK cells for the treatment of AML$366,000
R01 · FY2020 · CA · contact PI
Research Training in Academic Medical Oncology$362,121
T32 · FY2020 · CA
Project 4: Off-the-shelf engineered cord blood-derived natural killer cells for the treatment acute lymphoblastic leukemia$232,221
P50 · FY2020 · CA · contact PI
Off-the-shelf engineered NK cells for the treatment of AML$162,000
R01 · FY2020 · CA · contact PI
Off-the-Shelf Engineered Cord Blood NK Cells for the Treatment of Hematologic Malignancies.$480,131
P01 · FY2019 · CA · contact PI
Hematopoietic Progenitor Cells- Cord Blood$368,600
R01 · FY2019 · CA
Off-the-shelf engineered NK cells for the treatment of AML$355,019
R01 · FY2019 · CA · contact PI
Project 4: Off-the-shelf engineered cord blood-derived natural killer cells for the treatment acute lymphoblastic leukemia$272,373
P50 · FY2019 · CA · contact PI
Off-the-Shelf Engineered Cord Blood NK Cells for the Treatment of Hematologic Malignancies.$518,642
P01 · FY2018 · CA · contact PI
Hematopoietic Progenitor Cells- Cord Blood$380,000
R01 · FY2018 · CA
Off-the-shelf engineered NK cells for the treatment of AML$366,000
R01 · FY2018 · CA · contact PI
Project 4: Off-the-shelf engineered cord blood-derived natural killer cells for the treatment acute lymphoblastic leukemia$238,194
P50 · FY2018 · CA · contact PI
Hematopoietic Progenitor Cells- Cord Blood$380,000
R01 · FY2017 · CA
Off-the-shelf engineered NK cells for the treatment of AML$366,000
R01 · FY2017 · CA · contact PI
CMV Infection and NK-Cell Therapy for Multiple Myeloma$178,597
R21 · FY2017 · CA
Hematopoietic Progenitor Cells- Cord Blood$380,000
R01 · FY2016 · CA
CMV infection and NK-cell therapy for multiple myeloma$211,261
R21 · FY2016 · CA